Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winquist

Showing results (141-150 of 234) with videos related to

Pageof 24
Sort By:
Endocrine Pathology|December 6, 2024
Correction: Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer ManagementOzgur Mete, Andrée Boucher, Kasmintan A Schrader, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group StudyLillian L Siu, Denis Soulieres, Eric X Chen, et al.
Endocrine Pathology|November 23, 2024
Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer ManagementOzgur Mete, Andrée Boucher, Kasmintan A Schrader, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinomaChristine Elser, Lillian L Siu, Eric Winquist, et al.
Frontiers in Oncology|November 19, 2024
Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinomaShereen Ezzat, Jesse D Pasternak, Murali Rajaraman, et al.
European Journal of Human Genetics : EJHG|July 18, 2013
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer careFiona A Miller, Robin Z Hayeems, Jessica P Bytautas, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 22, 2013
High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancerAnthony C Nichols, David A Palma, Winsion Chow, et al.
British Journal of Clinical Pharmacology|January 19, 2023
Metabolomic identification of predictive and early biomarkers of cisplatin-induced acute kidney injury in adult head and neck cancer patientsYong Jin Lim, Steven G Xiu, M Sara Kuruvilla, et al.
Investigational New Drugs|November 27, 2007
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neckPatricia A Tang, Lillian L Siu, Eric X Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2026
What is the Impact of Treatment De-Escalation on Patient Reported Outcomes in Patients with T1-T2 Oropharyngeal Cancers? A Secondary Analysis of the ORATOR StudiesAlexa Dang, David A Palma, Anthony C Nichols, et al.
Pageof 24

Showing results (141-150 of 234) with videos related to

Sort By:
Pageof 24
Endocrine Pathology|December 6, 2024
Correction: Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer ManagementOzgur Mete, Andrée Boucher, Kasmintan A Schrader, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group StudyLillian L Siu, Denis Soulieres, Eric X Chen, et al.
Endocrine Pathology|November 23, 2024
Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer ManagementOzgur Mete, Andrée Boucher, Kasmintan A Schrader, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinomaChristine Elser, Lillian L Siu, Eric Winquist, et al.
Frontiers in Oncology|November 19, 2024
Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinomaShereen Ezzat, Jesse D Pasternak, Murali Rajaraman, et al.
European Journal of Human Genetics : EJHG|July 18, 2013
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer careFiona A Miller, Robin Z Hayeems, Jessica P Bytautas, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 22, 2013
High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancerAnthony C Nichols, David A Palma, Winsion Chow, et al.
British Journal of Clinical Pharmacology|January 19, 2023
Metabolomic identification of predictive and early biomarkers of cisplatin-induced acute kidney injury in adult head and neck cancer patientsYong Jin Lim, Steven G Xiu, M Sara Kuruvilla, et al.
Investigational New Drugs|November 27, 2007
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neckPatricia A Tang, Lillian L Siu, Eric X Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2026
What is the Impact of Treatment De-Escalation on Patient Reported Outcomes in Patients with T1-T2 Oropharyngeal Cancers? A Secondary Analysis of the ORATOR StudiesAlexa Dang, David A Palma, Anthony C Nichols, et al.
Pageof 24